Kura Oncology (KURA) Financials

$6.24 +0.04 (+0.65%)

Closing price 05/22/2025 04:00 PM Eastern

Extended Trading

$6.45 +0.21 (+3.37%)

As of 05/22/2025 06:53 PM Eastern

Annual Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-174	-153	-136
Consolidated Net Income / (Loss)	-174	-153	-136
Net Income / (Loss) Continuing Operations	-174	-153	-136
Total Pre-Tax Income	-172	-153	-136
Total Operating Income	-193	-166	-140
Total Gross Profit	54	0.00	0.00
Total Revenue	54	0.00	0.00
Operating Revenue	54	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	247	166	140
Selling, General & Admin Expense	77	51	47
Research & Development Expense	170	115	93
Total Other Income / (Expense), net	21	13	4.03
Interest Expense	1.62	1.55	0.23
Interest & Investment Income	23	15	4.25
Income Tax Expense	2.02	0.00	0.00
Basic Earnings per Share	($2.02)	($2.08)	($2.03)
Weighted Average Basic Shares Outstanding	86.16M	73.23M	66.99M
Diluted Earnings per Share	($2.02)	($2.08)	($2.03)
Weighted Average Diluted Shares Outstanding	86.16M	73.23M	66.99M
Weighted Average Basic & Diluted Shares Outstanding	80.75M	76.14M	68.44M

This table shows Kura Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-21	-53	-50	-50	-44	-37	-37	-34	-33	-36
Consolidated Net Income / (Loss)	-19	-54	-51	-50	-43	-39	-37	-34	-33	-36
Net Income / (Loss) Continuing Operations	-19	-54	-51	-50	-43	-39	-37	-34	-33	-36
Total Pre-Tax Income	-17	-54	-51	-50	-43	-39	-37	-34	-33	-36
Total Operating Income	-22	-60	-56	-54	-47	-42	-40	-37	-35	-37
Total Gross Profit	54	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	54	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	76	60	56	54	47	42	40	37	35	37
Selling, General & Admin Expense	24	18	17	18	14	13	12	11	12	12
Research & Development Expense	52	42	40	36	33	29	28	25	23	25
Total Other Income / (Expense), net	5.26	5.48	5.57	4.93	3.98	3.87	2.83	2.50	2.04	1.09
Interest Expense	0.40	0.41	0.41	0.40	0.39	0.40	0.39	0.36	0.23	0.00
Interest & Investment Income	5.66	5.89	5.97	5.33	4.37	4.28	3.22	2.86	2.27	1.09
Basic Earnings per Share	($0.21)	($0.63)	($0.59)	($0.59)	($0.55)	($0.50)	($0.53)	($0.50)	($0.49)	($0.53)
Weighted Average Basic Shares Outstanding	86.16M	86.95M	86.64M	83.91M	73.23M	77.24M	69.80M	68.40M	66.99M	66.89M
Diluted Earnings per Share	($0.21)	($0.63)	($0.59)	($0.59)	($0.55)	($0.50)	($0.53)	($0.50)	($0.49)	($0.53)
Weighted Average Diluted Shares Outstanding	86.16M	86.95M	86.64M	83.91M	73.23M	77.24M	69.80M	68.40M	66.99M	66.89M
Weighted Average Basic & Diluted Shares Outstanding	80.75M	77.76M	76.63M	76.18M	76.14M	74.27M	74.24M	68.44M	68.44M	66.90M

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	187	-14	-39
Net Cash From Operating Activities	134	-125	-110
Net Cash From Continuing Operating Activities	134	-125	-110
Net Income / (Loss) Continuing Operations	-174	-153	-136
Consolidated Net Income / (Loss)	-174	-153	-136
Depreciation Expense	0.85	0.85	0.76
Amortization Expense	-13	-8.94	1.68
Non-Cash Adjustments To Reconcile Net Income	35	27	27
Changes in Operating Assets and Liabilities, net	285	8.50	-3.55
Net Cash From Investing Activities	-102	16	33
Net Cash From Continuing Investing Activities	-102	16	33
Purchase of Property, Plant & Equipment	-0.47	-0.17	-0.63
Purchase of Investments	-659	-410	-271
Sale and/or Maturity of Investments	558	426	304
Net Cash From Financing Activities	154	95	39
Net Cash From Continuing Financing Activities	154	95	39
Repayment of Debt	0.00	0.00	-0.58
Issuance of Debt	0.00	0.00	10
Issuance of Common Equity	154	95	29
Cash Interest Paid	1.10	1.06	0.07

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	175	4.30	3.68	4.19	8.58	-20	22	-25	-39	52
Net Cash From Operating Activities	269	-43	-43	-49	-34	-29	-26	-36	-27	-21
Net Cash From Continuing Operating Activities	269	-43	-43	-49	-34	-29	-26	-36	-27	-21
Net Income / (Loss) Continuing Operations	-19	-54	-51	-50	-43	-39	-37	-34	-33	-36
Consolidated Net Income / (Loss)	-19	-54	-51	-50	-43	-39	-37	-34	-33	-36
Depreciation Expense	0.20	0.21	0.20	0.23	0.21	0.22	0.21	0.21	0.21	0.19
Amortization Expense	-2.75	-3.30	-3.42	-3.15	-2.61	-2.77	-1.99	-1.57	-0.58	0.37
Non-Cash Adjustments To Reconcile Net Income	9.32	7.82	8.97	8.74	5.70	7.37	7.30	7.02	7.15	6.59
Changes in Operating Assets and Liabilities, net	282	6.24	2.56	-5.15	5.17	4.76	6.03	-7.46	-0.19	7.35
Net Cash From Investing Activities	-95	46	43	-95	42	8.56	-46	11	-47	72
Net Cash From Continuing Investing Activities	-95	46	43	-95	42	8.56	-46	11	-47	72
Purchase of Property, Plant & Equipment	-0.37	-	-0.02	-0.08	-0.02	-0.02	-0.10	-0.04	-0.01	-0.38
Purchase of Investments	-241	-62	-162	-195	-100	-97	-140	-74	-106	-57
Sale and/or Maturity of Investments	146	107	205	100	142	105	93	85	59	129
Net Cash From Financing Activities	0.81	2.20	3.04	148	0.69	0.08	94	0.00	35	0.88
Net Cash From Continuing Financing Activities	0.81	2.20	3.04	148	0.69	0.08	94	0.00	35	0.88
Issuance of Common Equity	0.81	2.20	3.04	148	0.69	0.08	94	0.00	25	0.88

This table presents Kura Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	760	449	456
Total Current Assets	745	432	446
Cash & Equivalents	224	37	52
Short-Term Investments	503	387	386
Prepaid Expenses	17	8.52	8.44
Plant, Property, & Equipment, net	1.68	1.86	2.54
Total Noncurrent Assets	14	15	7.34
Other Noncurrent Operating Assets	14	15	7.34
Total Liabilities & Shareholders' Equity	760	449	456
Total Liabilities	347	52	36
Total Current Liabilities	79	35	24
Short-Term Debt	2.61	0.00	-
Accounts Payable	50	34	22
Current Deferred Revenue	24	0.00	-
Other Current Liabilities	1.88	1.51	2.32
Total Noncurrent Liabilities	268	16	12
Long-Term Debt	6.92	9.33	9.16
Noncurrent Deferred Revenue	254	0.00	-
Other Noncurrent Operating Liabilities	6.99	7.07	2.81
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	414	397	420
Total Preferred & Common Equity	414	397	420
Preferred Stock	0.00	0.00	0.00
Total Common Equity	414	397	420
Common Stock	1,308	1,120	997
Retained Earnings	-895	-721	-569
Accumulated Other Comprehensive Income / (Loss)	0.76	-1.27	-8.03

This table presents Kura Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	479	515	554	474	495	426	448
Total Current Assets	463	500	538	460	486	416	436
Cash & Equivalents	49	45	42	29	49	27	91
Short-Term Investments	406	446	486	424	428	379	337
Prepaid Expenses	7.89	8.25	11	7.32	8.67	11	8.62
Plant, Property, & Equipment, net	1.32	1.52	1.71	2.06	2.25	2.37	2.73
Total Noncurrent Assets	14	14	14	12	6.84	7.16	8.86
Other Noncurrent Operating Assets	14	14	14	12	6.84	7.16	8.86
Total Liabilities & Shareholders' Equity	479	515	554	474	495	426	448
Total Liabilities	55	49	49	44	35	31	28
Total Current Liabilities	40	33	32	28	24	19	25
Short-Term Debt	1.72	0.85	-	-	-	-	-
Accounts Payable	37	31	31	26	22	17	22
Other Current Liabilities	1.69	1.47	1.36	1.68	2.35	2.33	2.30
Total Noncurrent Liabilities	15	16	17	16	11	12	3.62
Long-Term Debt	7.76	8.58	9.38	9.29	9.24	9.20	-
Other Noncurrent Operating Liabilities	6.94	7.02	7.18	7.02	1.92	2.36	3.62
Total Equity & Noncontrolling Interests	424	466	505	430	460	395	420
Total Preferred & Common Equity	424	466	505	430	460	395	420
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	424	466	505	430	460	395	420
Common Stock	1,299	1,288	1,277	1,112	1,105	1,004	965
Retained Earnings	-876	-822	-771	-679	-640	-603	-536
Accumulated Other Comprehensive Income / (Loss)	1.12	-0.46	-0.82	-3.54	-5.22	-5.90	-9.42

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-17.87%	-26.54%	-9.14%
EBIT Growth	-16.52%	-18.55%	-6.56%
NOPAT Growth	-16.52%	-18.55%	-6.56%
Net Income Growth	-13.99%	-12.36%	-4.12%
EPS Growth	2.88%	-2.46%	-3.05%
Operating Cash Flow Growth	207.61%	-13.41%	-5.27%
Free Cash Flow Firm Growth	241.38%	-6.51%	-5.24%
Invested Capital Growth	-1,653.30%	-102.97%	24.69%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	10.55%	-8.51%	-3.21%
EBIT Q/Q Growth	11.18%	-7.53%	-1.54%
NOPAT Q/Q Growth	11.18%	-7.53%	-1.54%
Net Income Q/Q Growth	11.93%	-6.77%	-0.27%
EPS Q/Q Growth	14.41%	-2.97%	0.49%
Operating Cash Flow Q/Q Growth	179.42%	-6.65%	-2.96%
Free Cash Flow Firm Q/Q Growth	205.63%	-4.41%	-2.81%
Invested Capital Q/Q Growth	-1,279.49%	-29.81%	-4.84%
Profitability Metrics	-	-	-
Gross Margin	100.00%	0.00%	0.00%
EBITDA Margin	-380.39%	0.00%	0.00%
Operating Margin	-358.55%	0.00%	0.00%
EBIT Margin	-358.55%	0.00%	0.00%
Profit (Net Income) Margin	-322.89%	0.00%	0.00%
Tax Burden Percent	101.17%	100.00%	100.00%
Interest Burden Percent	89.01%	92.06%	97.12%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-42.91%	-37.34%	-29.31%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-31.96%	0.00%	0.00%
Return on Assets (ROA)	-28.78%	0.00%	0.00%
Return on Common Equity (ROCE)	-42.91%	-37.34%	-29.31%
Return on Equity Simple (ROE_SIMPLE)	-42.06%	-38.42%	-32.32%
Net Operating Profit after Tax (NOPAT)	-135	-116	-98
NOPAT Margin	-250.98%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-6.84%	-8.67%	-8.01%
Return On Investment Capital (ROIC_SIMPLE)	-31.96%	-28.54%	-22.80%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	143.11%	0.00%	0.00%
R&D to Revenue	315.44%	0.00%	0.00%
Operating Expenses to Revenue	458.55%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-193	-166	-140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-205	-174	-137
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.64	2.69	1.98
Price to Tangible Book Value (P/TBV)	1.64	2.69	1.98
Price to Revenue (P/Rev)	12.57	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.02	0.02
Long-Term Debt to Equity	0.02	0.02	0.02
Financial Leverage	-1.40	-1.03	-1.02
Leverage Ratio	1.49	1.11	1.07
Compound Leverage Factor	1.33	1.02	1.04
Debt to Total Capital	2.25%	2.30%	2.13%
Short-Term Debt to Total Capital	0.62%	0.00%	0.00%
Long-Term Debt to Total Capital	1.63%	2.30%	2.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.75%	97.70%	97.87%
Debt to EBITDA	-0.05	-0.05	-0.07
Net Debt to EBITDA	3.50	2.38	3.12
Long-Term Debt to EBITDA	-0.03	-0.05	-0.07
Debt to NOPAT	-0.07	-0.08	-0.09
Net Debt to NOPAT	5.31	3.57	4.38
Long-Term Debt to NOPAT	-0.05	-0.08	-0.09
Altman Z-Score	-0.19	10.00	12.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.46	12.26	18.56
Quick Ratio	9.24	12.02	18.21
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	152	-107	-101
Operating Cash Flow to CapEx	28,456.99%	-74,300.00%	-17,581.79%
Free Cash Flow to Firm to Interest Expense	93.66	-69.24	-439.77
Operating Cash Flow to Interest Expense	82.96	-80.58	-480.62
Operating Cash Flow Less CapEx to Interest Expense	82.67	-80.69	-483.35
Efficiency Ratios	-	-	-
Asset Turnover	0.09	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	30.43	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-304	-17	-8.55
Invested Capital Turnover	-0.34	0.00	0.00
Increase / (Decrease) in Invested Capital	-287	-8.80	2.80
Enterprise Value (EV)	-41	653	401
Market Capitalization	677	1,068	830
Book Value per Share	$5.32	$5.35	$6.28
Tangible Book Value per Share	$5.32	$5.35	$6.28
Total Capital	423	407	429
Total Debt	9.52	9.33	9.16
Total Long-Term Debt	6.92	9.33	9.16
Net Debt	-718	-415	-429
Capital Expenditures (CapEx)	0.47	0.17	0.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-59	-27	-16
Debt-free Net Working Capital (DFNWC)	669	397	422
Net Working Capital (NWC)	666	397	422
Net Nonoperating Expense (NNE)	39	37	38
Net Nonoperating Obligations (NNO)	-718	-415	-429
Total Depreciation and Amortization (D&A)	-12	-8.09	2.44
Debt-free, Cash-free Net Working Capital to Revenue	-108.89%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	1,241.07%	0.00%	0.00%
Net Working Capital to Revenue	1,236.23%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.02)	($2.08)	($2.03)
Adjusted Weighted Average Basic Shares Outstanding	86.16M	73.23M	66.99M
Adjusted Diluted Earnings per Share	($2.02)	($2.08)	($2.03)
Adjusted Weighted Average Diluted Shares Outstanding	86.16M	73.23M	66.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	80.75M	76.14M	68.44M
Normalized Net Operating Profit after Tax (NOPAT)	-135	-116	-98
Normalized NOPAT Margin	-250.98%	0.00%	0.00%
Pre Tax Income Margin	-319.15%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-119.33	-107.04	-610.76
NOPAT to Interest Expense	-83.53	-74.93	-427.53
EBIT Less CapEx to Interest Expense	-119.62	-107.15	-613.50
NOPAT Less CapEx to Interest Expense	-83.82	-75.04	-430.27
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	49.16%	-39.88%	-42.71%	-51.23%	-38.36%	-24.96%	-21.61%	-20.40%	-13.67%	-11.45%
EBIT Growth	51.98%	-40.99%	-41.00%	-48.91%	-33.01%	-16.07%	-13.22%	-11.54%	-6.41%	-8.66%
NOPAT Growth	51.98%	-40.99%	-41.00%	-48.91%	-33.01%	-16.07%	-13.22%	-11.54%	-6.41%	-8.66%
Net Income Growth	55.09%	-40.94%	-36.75%	-45.37%	-29.21%	-8.73%	-6.92%	-4.98%	-1.13%	-6.41%
EPS Growth	61.82%	-26.00%	-11.32%	-18.00%	-12.24%	5.66%	-1.92%	-2.04%	2.00%	-6.00%
Operating Cash Flow Growth	884.46%	-49.65%	-66.02%	-36.16%	-29.32%	-38.16%	15.57%	-11.47%	-13.54%	14.57%
Free Cash Flow Firm Growth	1,233.13%	-35.54%	-52.15%	3.34%	12.70%	9.70%	37.06%	8.54%	-1.75%	-7.30%
Invested Capital Growth	-1,653.30%	-64.99%	-98.91%	-734.67%	-102.97%	-63.93%	-950.46%	60.34%	24.69%	15.84%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	60.31%	-5.63%	-3.94%	-16.69%	-9.19%	-7.77%	-10.14%	-6.76%	1.39%	-4.88%
EBIT Q/Q Growth	62.50%	-6.17%	-3.58%	-16.45%	-10.10%	-6.17%	-9.40%	-4.01%	3.93%	-3.57%
NOPAT Q/Q Growth	62.50%	-6.17%	-3.58%	-16.45%	-10.10%	-6.17%	-9.40%	-4.01%	3.93%	-3.57%
Net Income Q/Q Growth	64.68%	-7.02%	-2.65%	-15.75%	-10.84%	-3.84%	-9.11%	-2.88%	6.73%	-2.11%
EPS Q/Q Growth	66.67%	-6.78%	0.00%	-7.27%	-10.00%	5.66%	-6.00%	-2.04%	7.55%	-1.92%
Operating Cash Flow Q/Q Growth	719.55%	-2.14%	12.93%	-42.37%	-18.19%	-13.31%	28.59%	-35.21%	-26.27%	30.75%
Free Cash Flow Firm Q/Q Growth	915.97%	-5.45%	-16.84%	-12.71%	2.40%	-18.38%	25.77%	-1.80%	-0.96%	17.50%
Invested Capital Q/Q Growth	-1,279.49%	-37.61%	-26.57%	27.03%	-29.81%	-65.91%	-431.11%	82.26%	-4.84%	-963.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-46.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-41.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-41.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-35.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	111.73%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	76.59%	90.85%	90.13%	90.95%	91.50%	90.89%	92.93%	93.17%	94.19%	97.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-42.91%	-46.28%	-39.27%	-37.34%	-37.34%	-33.65%	-30.77%	-31.55%	-29.31%	-28.42%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-3.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-3.18%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-42.91%	-46.28%	-39.27%	-37.34%	-37.34%	-33.65%	-30.77%	-31.55%	-29.31%	-28.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-46.62%	-39.00%	-33.28%	0.00%	-33.25%	-30.43%	-34.78%	0.00%	-32.28%
Net Operating Profit after Tax (NOPAT)	-16	-42	-39	-38	-33	-30	-28	-26	-25	-26
NOPAT Margin	-29.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-0.62%	-2.81%	-2.39%	-2.50%	-2.38%	-2.04%	-2.00%	-1.93%	-1.80%	-2.04%
Return On Investment Capital (ROIC_SIMPLE)	-3.71%	-	-	-	-8.05%	-	-	-	-5.73%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	44.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	97.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	141.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-22	-60	-56	-54	-47	-42	-40	-37	-35	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-25	-63	-60	-57	-49	-45	-42	-38	-36	-36
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.64	3.53	3.37	3.14	2.69	1.57	1.58	2.12	1.98	2.18
Price to Tangible Book Value (P/TBV)	1.64	3.53	3.37	3.14	2.69	1.57	1.58	2.12	1.98	2.18
Price to Revenue (P/Rev)	12.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.00
Long-Term Debt to Equity	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.00
Financial Leverage	-1.40	-1.04	-1.03	-1.02	-1.03	-1.03	-1.01	-1.01	-1.02	-1.02
Leverage Ratio	1.49	1.12	1.09	1.09	1.11	1.09	1.06	1.06	1.07	1.06
Compound Leverage Factor	1.14	1.01	0.98	0.99	1.01	0.99	0.99	0.99	1.01	1.03
Debt to Total Capital	2.25%	2.19%	1.98%	1.82%	2.30%	2.11%	1.97%	2.28%	2.13%	0.00%
Short-Term Debt to Total Capital	0.62%	0.40%	0.18%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	1.63%	1.79%	1.80%	1.82%	2.30%	2.11%	1.97%	2.28%	2.13%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.75%	97.81%	98.02%	98.18%	97.70%	97.89%	98.03%	97.72%	97.87%	100.00%
Debt to EBITDA	-0.05	-0.04	-0.04	-0.05	-0.05	-0.06	-0.06	-0.06	-0.07	0.00
Net Debt to EBITDA	3.50	1.95	2.28	2.68	2.38	2.77	3.09	2.76	3.12	0.00
Long-Term Debt to EBITDA	-0.03	-0.03	-0.04	-0.05	-0.05	-0.06	-0.06	-0.06	-0.07	0.00
Debt to NOPAT	-0.07	-0.06	-0.07	-0.07	-0.08	-0.09	-0.09	-0.09	-0.09	0.00
Net Debt to NOPAT	5.31	2.93	3.44	4.03	3.57	4.11	4.51	3.95	4.38	0.00
Long-Term Debt to NOPAT	-0.05	-0.05	-0.06	-0.07	-0.08	-0.09	-0.09	-0.09	-0.09	0.00
Altman Z-Score	0.55	14.40	17.68	18.29	10.87	8.06	11.43	15.16	12.94	18.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.46	11.47	14.94	16.67	12.26	16.71	20.32	21.65	18.56	17.64
Quick Ratio	9.24	11.28	14.69	16.34	12.02	16.44	19.96	21.10	18.21	17.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	271	-33	-32	-27	-24	-25	-21	-28	-27	-27
Operating Cash Flow to CapEx	72,347.04%	0.00%	-265,812.50%	-58,147.62%	-214,425.00%	-145,135.00%	-26,684.38%	-99,644.44%	-221,083.33%	-5,514.44%
Free Cash Flow to Firm to Interest Expense	672.86	-80.66	-77.62	-67.77	-60.74	-60.69	-53.52	-76.66	-119.70	0.00
Operating Cash Flow to Interest Expense	667.82	-105.44	-104.75	-122.72	-87.08	-71.85	-66.19	-98.55	-115.85	0.00
Operating Cash Flow Less CapEx to Interest Expense	666.90	-105.44	-104.79	-122.93	-87.12	-71.90	-66.44	-98.65	-115.90	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	30.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-304	-22	-16	-13	-17	-13	-8.06	-1.52	-8.55	-8.15
Invested Capital Turnover	-0.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-287	-8.69	-7.97	-11	-8.80	-5.21	-7.29	2.31	2.80	1.54
Enterprise Value (EV)	-41	1,052	1,086	1,066	653	234	256	440	401	486
Market Capitalization	677	1,497	1,569	1,584	1,068	677	724	837	830	914
Book Value per Share	$5.32	$5.53	$6.12	$6.02	$5.35	$5.79	$6.72	$5.77	$6.28	$6.27
Tangible Book Value per Share	$5.32	$5.53	$6.12	$6.02	$5.35	$5.79	$6.72	$5.77	$6.28	$6.27
Total Capital	423	433	475	514	407	439	469	404	429	420
Total Debt	9.52	9.47	9.42	9.38	9.33	9.29	9.24	9.20	9.16	0.00
Total Long-Term Debt	6.92	7.76	8.58	9.38	9.33	9.29	9.24	9.20	9.16	0.00
Net Debt	-718	-446	-482	-518	-415	-443	-468	-397	-429	-428
Capital Expenditures (CapEx)	0.37	0.00	0.02	0.08	0.02	0.02	0.10	0.04	0.01	0.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-59	-31	-24	-22	-27	-20	-15	-8.68	-16	-16
Debt-free Net Working Capital (DFNWC)	669	425	467	506	397	432	462	397	422	412
Net Working Capital (NWC)	666	423	466	506	397	432	462	397	422	412
Net Nonoperating Expense (NNE)	3.50	12	11	11	10	8.87	9.17	8.47	8.50	9.89
Net Nonoperating Obligations (NNO)	-718	-446	-482	-518	-415	-443	-468	-397	-429	-428
Total Depreciation and Amortization (D&A)	-2.54	-3.10	-3.22	-2.91	-2.40	-2.55	-1.78	-1.37	-0.38	0.56
Debt-free, Cash-free Net Working Capital to Revenue	-108.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	1,241.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	1,236.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.21)	($0.63)	($0.59)	($0.59)	($0.55)	($0.50)	($0.53)	($0.50)	($0.49)	($0.53)
Adjusted Weighted Average Basic Shares Outstanding	86.16M	86.95M	86.64M	83.91M	73.23M	77.24M	69.80M	68.40M	66.99M	66.89M
Adjusted Diluted Earnings per Share	($0.21)	($0.63)	($0.59)	($0.59)	($0.55)	($0.50)	($0.53)	($0.50)	($0.49)	($0.53)
Adjusted Weighted Average Diluted Shares Outstanding	86.16M	86.95M	86.64M	83.91M	73.23M	77.24M	69.80M	68.40M	66.99M	66.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	80.75M	77.76M	76.63M	76.18M	76.14M	74.27M	74.24M	68.44M	68.44M	66.90M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-42	-39	-38	-33	-30	-28	-26	-25	-26
Normalized NOPAT Margin	-29.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-31.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.72	-145.35	-138.93	-136.81	-118.69	-105.13	-103.37	-100.46	-153.52	0.00
NOPAT to Interest Expense	-39.00	-101.74	-97.25	-95.77	-83.08	-73.59	-72.36	-70.32	-107.46	0.00
EBIT Less CapEx to Interest Expense	-56.64	-145.35	-138.97	-137.03	-118.73	-105.18	-103.62	-100.55	-153.57	0.00
NOPAT Less CapEx to Interest Expense	-39.93	-101.74	-97.29	-95.98	-83.12	-73.64	-72.60	-70.42	-107.52	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Kura Oncology's Financials

When does Kura Oncology's fiscal year end?

According to the most recent income statement we have on file, Kura Oncology's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Kura Oncology's net income changed over the last 2 years?

Kura Oncology's net income appears to be on an upward trend, with a most recent value of -$173.98 million in 2024, rising from -$135.84 million in 2022. The previous period was -$152.63 million in 2023. See Kura Oncology's forecast for analyst expectations on what’s next for the company.

What is Kura Oncology's operating income?

Kura Oncology's total operating income in 2024 was -$193.20 million, based on the following breakdown:

Total Gross Profit: $53.88 million
Total Operating Expenses: $247.08 million

How has Kura Oncology revenue changed over the last 2 years?

Over the last 2 years, Kura Oncology's total revenue changed from $0.00 in 2022 to $53.88 million in 2024, a change of 5,388,300,000.0%.

How much debt does Kura Oncology have?

Kura Oncology's total liabilities were at $346.52 million at the end of 2024, a 570.7% increase from 2023, and a 861.8% increase since 2022.

How much cash does Kura Oncology have?

In the past 2 years, Kura Oncology's cash and equivalents has ranged from $37.32 million in 2023 to $224.46 million in 2024, and is currently $224.46 million as of their latest financial filing in 2024.

How has Kura Oncology's book value per share changed over the last 2 years?

Over the last 2 years, Kura Oncology's book value per share changed from 6.28 in 2022 to 5.32 in 2024, a change of -15.3%.

Related Companies

This page (NASDAQ:KURA) was last updated on 5/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Financials

Frequently Asked Questions About Kura Oncology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Financials

Annual Income Statements for Kura Oncology

Quarterly Income Statements for Kura Oncology

Annual Cash Flow Statements for Kura Oncology

Quarterly Cash Flow Statements for Kura Oncology

Annual Balance Sheets for Kura Oncology

Quarterly Balance Sheets for Kura Oncology

Annual Metrics And Ratios for Kura Oncology

Quarterly Metrics And Ratios for Kura Oncology

Frequently Asked Questions About Kura Oncology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools